Home › Compare › QUISF vs ABBV
QUISF yields 512.56% · ABBV yields 3.06%● Live data
📍 QUISF pulled ahead of the other in Year 1
Combined, QUISF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QUISF + ABBV for your $10,000?
Quisitive Technology Solutions, Inc., through its subsidiaries, provides Microsoft solutions primarily in North America. It offers Microsoft cloud solutions, including Microsoft Azure, Microsoft Dynamics business applications, and Microsoft O365; CRG emPerform, an employee performance management software for small and medium sized business; and LedgerPay, a payment processing platform, as well as business solutions from other technology partners that are related to the Microsoft platform. The company also provides application development, business applications, data analytics, digital transformation, digital workplace, and infrastructure solutions; and cloud managed services, such as system administration and monitoring, as well as application maintenance, configurations, and upgrading. In addition, it offers solutions for healthcare, retail, and manufacturing industries, as well as for public sector. The company was formerly known as Nebo capital corp. and changed its name to Quisitive Technology Solutions, Inc. in August 2018. Quisitive Technology Solutions, Inc. is headquartered in Toronto, Canada.
Full QUISF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.